Core Viewpoint - The company, Tuoxin Pharmaceutical, announced that its subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained Self-GRAS status for its product, Glycyrrhizin Choline, from the FDA, which is a significant milestone for entering the U.S. and other international markets that recognize FDA standards [1] Group 1: Regulatory Approval - The product Glycyrrhizin Choline has passed the FDA's Generally Recognized as Safe (GRAS) evaluation, securing a key "passport" for market entry [1] - This certification is expected to facilitate the expansion into high-end food, dietary supplements, and special medical food markets globally [1] Group 2: Market Impact - The approval is anticipated to optimize the company's product structure and enhance overall profitability [1] - However, future market promotion may face challenges from policy adjustments and intensified market competition, leading to uncertainty regarding the sales contribution to the company's overall operations [1]
拓新药业：全资子公司产品通过美国Self-GRAS认证